Use of sex steroid function modulators to treat wounds and fibrotic disorders

• US 20070185068A1
• Filed: 04/05/2007
• Published: 08/09/2007
• Est. Priority Date: 07/22/1996
• Status: Abandoned Application

• Current Assignee: Renovo Ltd. (Bentley Park Ltd.)
• Original Assignee: Renovo Ltd. (Bentley Park Ltd.)
• Inventors: Ferguson, Mark, Ashcroft, Gillian
• Application Number:
  US11/730,991
• Publication Number:
  US 20070185068A1
• Time in Patent Office: Days
• US Class Current: 514/176
• CPC Class Codes: A61K 31/05 Phenols cannabinoids A61K31/658
• CPC Class Codes: A61K 31/135 having aromatic rings , e.g. ketamine, nortriptyline methadone A61K31/137
• CPC Class Codes: A61K 31/138 Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377
• CPC Class Codes: A61K 31/167 having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• CPC Class Codes: A61K 31/222 with compounds having aromatic groups, e.g. dipivefrine, ibopamine
• CPC Class Codes: A61K 31/4184 condensed with carbocyclic rings, e.g. benzimidazoles
• CPC Class Codes: A61K 31/4196 1,2,4-Triazoles
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61K 31/565 not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
• CPC Class Codes: A61K 31/566 having an oxo group in position 17, e.g. estrone
• CPC Class Codes: A61K 31/567 substituted in position 17 alpha, e.g. mestranol, norethandrolone
• CPC Class Codes: A61K 31/568 substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
• CPC Class Codes: A61K 31/5685 having an oxo group in position 17, e.g. androsterone
• CPC Class Codes: A61K 31/569 substituted in position 17 alpha, e.g. ethisterone
• CPC Class Codes: A61K 31/57 substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• CPC Class Codes: A61K 31/573 substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• CPC Class Codes: A61K 31/575 substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• CPC Class Codes: A61K 31/58 containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin digitoxin A61K31/7048
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 13/12 : of the kidneys
• CPC Class Codes: A61P 15/08 : for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• CPC Class Codes: A61P 17/00 : Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 : for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 19/02 : for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/04 : for non-specific disorders of the connective tissue
• CPC Class Codes: A61P 21/00 : Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 25/00 : Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 : for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 27/02 : Ophthalmic agents
• CPC Class Codes: A61P 27/06 : Antiglaucoma agents or miotics
• CPC Class Codes: A61P 41/00 : Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/00 : Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/04 : Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Abstract

The present application relates to the use of compounds that influence the sex hormone system for the treatment of wounds and/or fibrotic disorders. Preferred compounds for use in such treatments are steroid hormones and especially the oestrogens.

Claims

1-39. -39. (canceled)

40. A method of accelerating the healing of wounds comprising administering to a person in need thereof a compound that promotes androgenic activity.

41. The method as claimed in claim 40 wherein the wound is a skin wound.

42. The method as claimed in claim 40 wherein said compound is an androgen hormone or androgen receptor agonist selected from the group consisting of:

testosterone, dihydrotestosterone, 5α

-androstanediol, testosterone undecanoate, testosterone enanthate, testosterone esters, testosterone proprionate, mesterolone, danazol and gesttrinone.

43. The method as claimed in claim 40 wherein said compound is selected from the group consisting of:

an inhibitor of androgen breakdown or an inhibitor of androgen receptor agonist breakdown;

a modulator of the activity of luteinising hormone, follicle stimulating hormone or chorionic gonadotrophin.

44. The method as claimed in claim 43 wherein said compound is an inhibitor of androgen breakdown or an inhibitor of androgen receptor agonist breakdown and is aminoglutethamide.

45. The method as claimed in claim 40 wherein said compound is applied non-systemically.

46. The method as claimed in claim 40 wherein said compound is formulated as a liquid, ointment, cream, gel, hydrogel, powder, aerosol or implant.

47. The method as claimed in claim 40 wherein said compound is formulated as eye drops.

48. The method as claimed in claim 40 wherein a medicament comprising 0.001% to 4% by weight of said compound is administered to the person.

49. A method of inhibiting fibrosis comprising administering to a person in need thereof a compound that inhibits androgenic activity.

50. The method as claimed in claim 49 wherein said compound is an androgen receptor antagonist.

51. The method as claimed in claim 50 wherein said compound is cyproterone acetate or flutamide.

52. The method as claimed in claim 49 wherein said compound is an inhibitor of androgen production.

53. The method as claimed in claim 49 wherein said compound is applied non-systemically.

54. The method as claimed in claim 49 wherein said compound is formulated as a liquid, ointment, cream, gel, hydrogel, powder, aerosol or implant.

55. The method as claimed in claim 49 wherein said compound is formulated as eye drops.

56. The method as claimed in claim 49 wherein a medicament comprising 0.001% to 4% by weight of said compound is administered to the person.

57. The method as claimed in claim 49 for reducing or preventing scarring.

58. A method of inhibiting fibrosis comprising administering to a person in need thereof a compound that promotes progesterone activity.

59. The method as claimed in claim 58 wherein said compound is progesterone or a progesterone receptor agonist selected from the group of compounds consisting of:

allyoestrenol, desogestrel, dydrogesterone, ethynodiol diacetate, gestodene, gestranol hexanoate, hydroxyprogesterone hexanoate, levonorgestrel, megestrol acetate, medroxyprogesterone acetate, norethisterone, norethisterone acetate, norethisterone enanthate, norgestimate or norgesterel.

60. The method as claimed in claim 58 wherein the compound is selected from the group of compounds consisting of:

an inhibitor of progesterone breakdown or an inhibitor of progesterone receptor agonist breakdown;

or a modulator of the activity of luteinising hormone, follicle stimulating hormone or chorionic gonadotrophin.

61. The method as claimed in claim 58 wherein said compound is applied non-systemically.

62. The method as claimed in claim 58 wherein said compound is formulated as a liquid, ointment, cream, gel, hydrogel, powder, aerosol or implant.

63. The method as claimed in claim 58 wherein said compound is formulated as eye drops.

64. The method as claimed in claim 58 wherein a medicament comprising 0.001% to 4% by weight of said compound is administered to the person.

65. The method as claimed in claim 58 for reducing or preventing scarring.

66. A method of accelerating the healing of wounds comprising administering to a person in need thereof a sex steroid hormone precursor.

67. The method as claimed in claim 66 wherein said compound is a precursor of an oestrogen or androgenic sex steroid hormone.

68. The method as claimed in claim 66 wherein said compound is Dehydroepiandrosterone (DHEA) or DHEA sulphate (DHEAS).

69. The method as claimed in claim 66 wherein said compound is applied non-systemically.

70. The method as claimed in claim 66 wherein said compound is formulated as a liquid, ointment, cream, gel, hydrogel, powder, aerosol or implant.

71. The method as claimed in claim 66 wherein said compound is formulated as eye drops.

72. The method as claimed in claim 66 wherein a medicament comprising 0.001% to 4% by weight of said compound is administered to the person.